This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vivus Piles New Debt On Top Of Excuses (Updated)

Stepping back from the positives and negatives of the loan, the fact that Vivus needs more money now reeks of desperation. The company ended 2012 with $214 million in cash and marketable securities. Taking on another $50 million in debt now -- plus $60 million later this year -- is a signal that current Qsymia marketing efforts are not gaining traction with doctors or obese Americans. Management expects to spend a lot more money -- and lose a lot more money -- into the foreseeable future. [At least Vivus has a weight-loss pill to sell. <b>Arena Pharmaceuticals</b> <span class=" TICKERFLAT">(<a href="/quote/ARNA.html">ARNA</a> - <a href="http://secure2.thestreet.com/cap/prm.do?OID=028198&amp;ticker=ARNA">Get Report</a><a class=" arrow" href="/quote/ARNA.html"><span class=" tickerChange" id="story_ARNA"></span></a>)</span> can't seem to get its drug Belviq out of the starting gate.]

And then there's Stendra. Forgotten about Vivus' erectile dysfunction drug? You're not alone. FDA approved Stendra last April -- almost one year ago -- but the drug remains on the shelf because Vivus has been unable to find any company willing to buy it.

Shares of Vivus were down 3.6% to $10.54 in Tuesday trading.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
VVUS $1.50 -14.00%
ARNA $4.04 1.60%
GOOG $626.43 -0.97%
TSLA $266.11 -0.25%
YHOO $36.69 -2.00%

Markets

Chart of I:DJI
DOW 17,690.46 -55.52 -0.31%
S&P 500 2,104.64 -3.99 -0.19%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs